MicroPort Endovascular MedTech Ltd (688016) — Capital Reinvestment Ratio

Latest as of September 2025: 1.84x

MicroPort Endovascular MedTech Ltd (688016) has a Capital Reinvestment Ratio of 1.84x as of September 2025, meaning it reinvests 2% of its operating cash flow (CN¥46.79 Million) in capital expenditures (CN¥86.03 Million). See 688016 net asset quality score to measure how much of total assets are equity-financed.

Capital Reinvestment Ratio

1.84x
Capex / Operating Cash Flow

Operating Cash Flow

CN¥46.79 Million
CNY

Capital Expenditures

CN¥86.03 Million
CNY

Data as of

Sep 2025
Most recent filing

MicroPort Endovascular MedTech Ltd Capital Reinvestment Ratio (2016–2025)

This chart tracks MicroPort Endovascular MedTech Ltd's Capital Reinvestment Ratio across 10 annual periods. Check MicroPort Endovascular MedTech Ltd total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.

Annual Capital Reinvestment Ratio for MicroPort Endovascular MedTech Ltd (2016–2025)

Year-by-year Capital Reinvestment Ratio for MicroPort Endovascular MedTech Ltd from 2016 to 2025. For live market cap and broader valuation context, see market cap of MicroPort Endovascular MedTech Ltd.

Year Reinvestment Ratio Operating CF (CNY) Capital Expenditures YoY Change
2025 0.53x CN¥573.06 Million CN¥303.03 Million ▼ -7.1%
2024 0.57x CN¥373.60 Million CN¥212.65 Million ▲ +70.9%
2023 0.33x CN¥571.22 Million CN¥190.26 Million ▼ -62.2%
2022 0.88x CN¥333.76 Million CN¥293.98 Million ▲ +195.2%
2021 0.30x CN¥300.25 Million CN¥89.58 Million ▲ +147.4%
2020 0.12x CN¥217.44 Million CN¥26.22 Million ▼ -18.7%
2019 0.15x CN¥143.20 Million CN¥21.24 Million ▼ -36.4%
2018 0.23x CN¥106.85 Million CN¥24.90 Million ▼ -42.7%
2017 0.41x CN¥69.36 Million CN¥28.23 Million ▼ -61.4%
2016 1.06x CN¥30.13 Million CN¥31.81 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow